These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11453308)

  • 21. Cytochrome P450 polymorphisms as risk factors for steroid hormone-related cancers.
    Friedberg T
    Am J Pharmacogenomics; 2001; 1(2):83-91. PubMed ID: 12174676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nutrition, genetics, and risks of cancer.
    Rock CL; Lampe JW; Patterson RE
    Annu Rev Public Health; 2000; 21():47-64. PubMed ID: 10884945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers.
    Bartsch H; Nair U; Risch A; Rojas M; Wikman H; Alexandrov K
    Cancer Epidemiol Biomarkers Prev; 2000 Jan; 9(1):3-28. PubMed ID: 10667460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tag single nucleotide polymorphisms of alcohol-metabolizing enzymes modify the risk of upper aerodigestive tract cancers: HapMap database analysis.
    Chung CS; Lee YC; Liou JM; Wang CP; Ko JY; Lee JM; Wu MS; Wang HP
    Dis Esophagus; 2014 Jul; 27(5):493-503. PubMed ID: 23088731
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic polymorphism of cytochrome P450 as a biomarker of susceptibility to environmental toxicity.
    Hong JY; Yang CS
    Environ Health Perspect; 1997 Jun; 105 Suppl 4(Suppl 4):759-62. PubMed ID: 9255558
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic polymorphism and their contribution to cancer susceptibility.
    Conforti-Froes N; el-Zein R; Au W
    Cad Saude Publica; 1998; 14 Suppl 3():7-13. PubMed ID: 9819460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytochrome P-450 and acetyltransferase expression as biomarkers of carcinogen-DNA adduct levels and human cancer susceptibility.
    Badawi AF; Stern SJ; Lang NP; Kadlubar FF
    Prog Clin Biol Res; 1996; 395():109-40. PubMed ID: 8895986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Interindividual differences in efficacy and toxicity induced by therapeutic drugs and xenobiotics in relation to genetic polymorphisms in xenobiotic metabolizing enzymes].
    Ozawa S
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 1998; (116):69-81. PubMed ID: 10097514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug metabolism polymorphisms as modulators of cancer susceptibility.
    Taningher M; Malacarne D; Izzotti A; Ugolini D; Parodi S
    Mutat Res; 1999 May; 436(3):227-61. PubMed ID: 10354524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic polymorphisms and cancer susceptibility.
    Smith G; Stanley LA; Sim E; Strange RC; Wolf CR
    Cancer Surv; 1995; 25():27-65. PubMed ID: 8718512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Diagnosis of hepatic enzyme activities of drug metabolizing enzymes-phenotyping and genotyping].
    Ozawa S
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 1999; (117):63-76. PubMed ID: 10859937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of cytochrome P-450 genetic polymorphisms in oral carcinogenesis.
    Hernando-Rodriguez M; Rey-Barja N; Marichalar-Mendia X; Rodriguez-Tojo MJ; Acha-Sagredo A; Aguirre-Urizar JM
    J Oral Pathol Med; 2012 Jan; 41(1):1-8. PubMed ID: 21793938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Understanding the role of xenobiotic-metabolism in chemical carcinogenesis using gene knockout mice.
    Gonzalez FJ; Kimura S
    Mutat Res; 2001 Jun; 477(1-2):79-87. PubMed ID: 11376689
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Genetic polymorphisms on drug metabolizing enzymes in relation to anti-cancer drug effectiveness].
    Ozawa S
    Rinsho Byori; 2003 Feb; 51(2):168-73. PubMed ID: 12690635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Genetic polymorphisms in xenobiotic metabolizing enzymes as a determinant of susceptibility to environmental mutagens and carcinogens in humans].
    Ozawa S
    Yakugaku Zasshi; 1997 Nov; 117(10-11):895-909. PubMed ID: 9414599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer therapy and polymorphisms of cytochromes P450.
    MacLeod SL; Nowell S; Massengill J; Jazieh A; McClure G; Plaxco J; Kadlubar FF; Lan NP
    Clin Chem Lab Med; 2000 Sep; 38(9):883-7. PubMed ID: 11097344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic polymorphisms in human drug-metabolizing enzymes: potential uses of reverse genetics to identify genes of toxicological relevance.
    Puga A; Nebert DW; McKinnon RA; Menon AG
    Crit Rev Toxicol; 1997 Mar; 27(2):199-222. PubMed ID: 9099519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer.
    Sachse C; Smith G; Wilkie MJ; Barrett JH; Waxman R; Sullivan F; Forman D; Bishop DT; Wolf CR;
    Carcinogenesis; 2002 Nov; 23(11):1839-49. PubMed ID: 12419832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Interactions between genetics and the environment: the example of tumors].
    Vineis P
    Epidemiol Prev; 1995 Mar; 19(62):79-81. PubMed ID: 7541366
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.